Introduction
Methods
Sample collection
Laboratory
Protein array
ELISA
Statistic evaluation
Results
Patients
CRPS
Trauma control
RA
AxSpA
Psoriatic arthritis
FID CI−
FID CI+
Blood donors
Protein array results
Evaluation of different ELISA detection methods
Frequency in CRPS | ||||||||
---|---|---|---|---|---|---|---|---|
A1-23 | A24-44 | A44-70 | A71r3 | A94-114 | A120-165 | p291 NG4 protein | IC | |
Cut-offs | ||||||||
IgG | ||||||||
0/22 T | 5/26 (19%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 5/26 (19%) | 1/26 (4%) | 5/26 (19%) |
1/22 T | 5/26 (19%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 2/26 (8%) | 5/26 (19%) | 3/26 (12%) | 7/26 (27%) |
2/22 T | 6/26 (23%) | 1/26 (4%) | 2/26 (8%) | 4/26 (15%) | 4/26 (15%) | 6/26 (23%) | 6/26 (23%) | 8/26 (31%) |
3/22 T | 7/26 (27%) | 2/26 (8%) | 2/26 (8%) | 8/26 (31%) | 5/26 (19%) | 7/26 (27%) | 8/26 (31%) | 11/26 (42%) |
IgG1 | ||||||||
0/22 T | 1/26 (4%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 2/26 (8%) |
1/22 T | 2/26 (8%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 1/26 (4%) | 0/26 (0%) | 1/26 (4%) | 5/26 (19%) |
2/22 T | 5/26 (19%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 5/26 (19%) | 8/26 (31%) | 3/26 (12%) | 8/26 (31%) |
3/22 T | 5/26 (19%) | 2/26 (8%) | 4/26 (15%) | 3/26 (12%) | 6/26 (23%) | 11/26 (42%) | 5/26 (19%) | 11/26 (42%) |
IgG2 | ||||||||
0/22 T | 1/26 (4%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 0/26 (0%) | 1/26 (4%) | 0/26 (0%) |
1/22 T | 4/26 (15%) | 1/26 (4%) | 2/26 (8%) | 1/26 (4%) | 2/26 (8%) | 3/26 (12%) | 2/26 (8%) | 0/26 (0%) |
2/22 T | 5/26 (19%) | 2/26 (8%) | 4/26 (15%) | 3/26 (12%) | 6/26 (23%) | 7/26 (27%) | 2/26 (8%) | 2/26 (8%) |
3/22 T | 7/26 (27%) | 2/26 (8%) | 4/26 (15%) | 3/26 (12%) | 6/26 (23%) | 8/26 (31%) | 5/26 (19%) | 2/26 (8%) |
IgG3 | ||||||||
0/22 T | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 4/26 (15%) |
1/22 T | 2/26 (8%) | 1/26 (4%) | 1/26 (4%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 4/26 (15%) |
2/22 T | 4/26 (15%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 4/26 (15%) | 2/26 (8%) | 4/26 (15%) |
3/22 T | 4/26 (15%) | 4/26 (15%) | 2/26 (8%) | 4/26 (15%) | 4/26 (15%) | 4/26 (15%) | 5/26 (19%) | 5/26 (19%) |
IgG4 | ||||||||
0/22 T | 4/26 (15%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 3/26 (12%) | 0/26 (0%) |
1/22 T | 4/26 (15%) | 2/26 (8%) | 0/26 (0%) | 0/26 (0%) | 2/26 (8%) | 1/26 (4%) | 3/26 (12%) | 0/26 (0%) |
2/22 T | 4/26 (15%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 5/26 (19%) | 2/26 (8%) | 3/26 (12%) | 4/26 (15%) |
3/22 T | 4/26 (15%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 6/26 (23%) | 3/26 (12%) | 4/26 (15%) | 4/26 (15%) |
IgA | ||||||||
0/22 T | 1/26 (4%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 0/26 (0%) | 1/26 (4%) | 0/26 (0%) |
1/22 T | 5/26 (19%) | 1/26 (4%) | 2/26 (4%) | 1/26 (4%) | 2/26 (8%) | 3/26 (12%) | 2/26 (8%) | 0/26 (0%) |
2/22 T | 5/26 (19%) | 2/26 (8%) | 2/26 (4%) | 2/26 (8%) | 5/26 (19%) | 11/26 (42%) | 7/26 (27%) | 2/26 (8%) |
3/22 T | 7/26 (27%) | 2/26 (8%) | 4/26 (15%) | 3/26 (12%) | 6/26 (23%) | 12/26 (50%) | 8/26 (31%) | 2/26 (8%) |
IgM | ||||||||
0/22 T | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) |
1/22 T | 2/26 (8%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 0/26 (0%) |
2/22 T | 2/26 (8%) | 1/26 (4%) | 1/26 (4%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) | 2/26 (8%) |
CRPS | RA | SpA | PsA | FID CI+ | FID CI− | Trauma control | BD | |
---|---|---|---|---|---|---|---|---|
Anti-A1-23 IgG | 7/36 19% | 9/64 14% | 11/53 21% | 4/29 14% | 28/44 64% | 34/68 50% | 0/20 0% | 2/100 2% |
Anti-A120-165 IgG | 6/36 17% | 12/64 19% | 9/53 17% | 3/29 10% | 23/44 53% | 26/68 38% | 0/20 0% | 2/100 2% |
Anti-A10-165 IgA | 15/36 42% | 8/64 13% | 4/53 8% | 3/29 10% | 22/44 50% | 22/68 32% | 2/22 9% | 4/100 4% |
P29ING4 IgG IC | 11/36 31% | 17/64 27% | 13/53 25% | 5/29 17% | 5/44 11% | 3/68 4% | 1/22 5% | 4/100 4% |
P29ING4 IgG1 IC | 14/36 39% | 19/64 30% | 13/53 25% | 1/29 3% | 11/44 25% | 6/68 9% | 2/22 9% | 4/100 4% |
Combination of both IC tests | 16/36 44% | 28/64 44% | 16/53 30% | 5/29 17% | 13/44 30% | 9/68 13% | 3/22 14% | 8/100 8% |
Combination of IgG IC, anti-A120-165 IgA and IgG | 25/36 69% | 28/64 44% | 16/53 30% | 6/29 21% | 29/44 66% | 31/68 46% | 2/22 9% | 8/100 8% |